GenomicMD the Future of Personalized Medicine

Join our community today to learn more about your unique genetic predispositions for common diseases.

A New, Unique Screening for Major Diseases Trusted by Precision Health Leaders

The first-of-its-kind genomic (not just genetic) screening to be implemented by a major precision healthcare system.  

"This is a major advancement in the field of genomics and a powerful new tool to improve patient care.” Dr. Jianfeng Xu, Endeavor Health Vice President of Translational Research, the lead collaborating scientist. 

How Is Our Test Different?

On average, every person has three to four million variants in their DNA. These genetic changes are what make us unique: from visible, physical traits like eye color and height to more hidden ones such as our risk for developing diseases.
The Lifetime Genomics Risk Assessment (LGRA) is a unique screening test that uses a saliva or blood sample to analyze millions of common genetic variants to predict an individual’s risk for developing different health conditions. This resulting estimate is called a “polygenic risk score,” – frequently abbreviated as “PRS.”
PRS_PrCA

Why Polygenic?

Using the above prostate cancer study as an example, rare gene mutations associated with prostate cancer occur in 2% of the population, and 7% of men have a known family history of the disease. Meanwhile, the LGRA, which uses a polygenic risk score (PRS), has demonstrated the ability to identify 19% of men as being at increased risk.
Not a Typical Genetic Panel
Some genetic screening tests evaluate “rare pathogenic mutations,” which are variants that very few have but are associated with severe disease risk. This panel only looks at genes, so it is limited. A well-known example is a BRCA mutation, which can increase the risk for breast and other cancers. Depending on the disease, these occur in only 1-3% of the population.  In contrast, the LGRA assesses millions of common variants frequently occurring in the population. The LGRA has demonstrated the ability to identify 10-20% of individuals with an increased genomic predisposition to disease, with greater coverage than single-gene tests.
The Lifetime Genomics Risk Assessment
Our evidence-backed, advanced genomic assessments span many common diseases, including the following:
Cancer
Breast, prostate, colorectal, & ovarian
Cardiovascular Disease
Coronary artery disease and venous thromboembolism, two leading causes of death annually
Diabetes
Type 1 is most often diagnosed in childhood, but Type 2 is correlated to genomic variants and differs in terms of its treatment
Alzheimer's
Alzheimers is related to a variety of genomic variants, and though no cure currently exists many would like to know their risk
Future Research
We partner with leading scientists to uncover research on numerous conditions such as additional types of cancer and cardiovascular disease, digestive diseases, neurological disorders, psychological disorders (such as substance abuse and mental health conditions), metabolic disease, autoimmune disease, pharmacogenomic (medicine related) sensitivities, etc. Our research focus is driven by the needs of our patients and physicians, and members of our community will receive access to additional screening and reports as new genomic evidence emerges.
how it works-1
 How It Works

After your healthcare provider has placed the order you will receive an email with a link to pay. If your sample is being collected at home, you will be asked to provide your shipping address during the payment process.

After we receive and process your sample, we will process the LGRA report and then send it to your ordering provider, who will release it to you. This entire process usually takes about 2-4 weeks.

CAD LGRAS
 What Can I Expect From The Results?

The LGRA is a screening test to predict the risk of developing a given disease compared to the average individual in the population. It should not be used for diagnostic purposes. It cannot be used to confirm or deny the existence of a given disease or to declare with absolute certainty that someone will or will not develop the condition. As with all genomic testing, it is important to note that this is just a single piece of the puzzle when determining a patient’s total risk – which can be influenced by many factors including genomics, family history, environment, and/or lifestyle. This means an “average risk'' result does not imply that a patient has NO risk of developing the disease, only that their DNA does not indicate an increased polygenic risk. 

Looking for more information?
Our public knowledge base houses detailed information about GenomicMD's Lifetime Genomics Risk Assessment, as well as Q&As on genetics, polygenic testing, and more! Returning patients and providers can log into their portal for additional curated information within our community knowledge base
Looking for more information?
Our public knowledge base houses detailed information about GenomicMD's Lifetime Genomics Risk Assessment, as well as Q&As on genomics, our risk assessments and disease coverage, and more!